Dyne Therapeutics, Inc.
DYN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $435 | $122 | $172 | $201 |
| Short-Term Investments | $207 | $1 | $84 | $176 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $17 | $6 | $10 | $6 |
| Total Curr. Assets | $659 | $129 | $266 | $382 |
| Property Plant & Equip (Net) | $30 | $33 | $38 | $41 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $2 | $2 | $2 | $2 |
| Total NC Assets | $32 | $36 | $41 | $43 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $691 | $165 | $306 | $426 |
| Liabilities | – | – | – | – |
| Payables | $7 | $23 | $5 | $4 |
| Short-Term Debt | $5 | $5 | $5 | $4 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $31 | $23 | $18 | $21 |
| Total Curr. Liab. | $42 | $51 | $28 | $29 |
| LT Debt | $19 | $23 | $26 | $29 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $19 | $23 | $26 | $29 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $24 | $27 | $30 | $33 |
| Total Liabilities | $61 | $74 | $54 | $57 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$950 | -$633 | -$397 | -$228 |
| AOCI | $0 | $0 | -$1 | -$0 |
| Other Equity | $1,580 | $724 | $650 | $597 |
| Total Equity | $630 | $91 | $252 | $368 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $691 | $165 | $306 | $426 |
| Net Debt | -$411 | -$94 | -$142 | -$168 |